Growing evidence supports the use of plasma levels of tau phosphorylated at threonine 181, amyloid-β, neurofilament light and glial fibrillary acidic protein as promising biomarkers for Alzheimer’s disease. The gene discussed is GFAP; the disease is early-onset autosomal dominant Alzheimer disease.